Potential Therapeutic Targets of Triple-negative Breast Cancer Based on Its Intrinsic Subtype

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Oct 27

PMID 29069872

Citations 36

Authors

Fangyuan Shao

Heng Sun

Chu-Xia Deng

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer, which is characterized as estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative. TNBC is the most difficult breast cancer subgroup to treat, due to its unresponsiveness to current clinical targeted therapies, high rate of recurrence, and poor prognosis. Thus, there is an urgent medical need to identify therapeutic targets and develop more effective stratified medicine for the treatment of TNBC. Here we review the potential therapeutic targets for TNBC based on its intrinsic subtype. We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. The careful analysis of these signaling pathways and therapeutic targets would have significant impact on the drug development and clinical trials, leading to effective therapies for this deadly disease.

Citing Articles

Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling.

Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B Cell Genom. 2025; 5(2):100765.

PMID: 39914387 PMC: 11872555. DOI: 10.1016/j.xgen.2025.100765.

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.

CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.

Lewis M, King C, Wisniewska K, Regner M, Coffey A, Kelly M Cancer Res. 2024; 84(21):3684-3700.

PMID: 39186674 PMC: 11534545. DOI: 10.1158/0008-5472.CAN-23-3995.

Defining the Regulatory Logic of Breast Cancer Using Single-Cell Epigenetic and Transcriptome Profiling.

Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B bioRxiv. 2024; .

PMID: 38948758 PMC: 11212881. DOI: 10.1101/2024.06.13.598858.

A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway.

Pardo I, Fagundes P, Oliveira R, Campregher P Einstein (Sao Paulo). 2024; 22:eRW0552.

PMID: 38324848 PMC: 10948095. DOI: 10.31744/einstein_journal/2024RW0552.

References

Safholm A, Tuomela J, Rosenkvist J, Dejmek J, Harkonen P, Andersson T . The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008; 14(20):6556-63. DOI: 10.1158/1078-0432.CCR-08-0711. View

Stirzaker C, Zotenko E, Song J, Qu W, Nair S, Locke W . Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Commun. 2015; 6:5899. DOI: 10.1038/ncomms6899. View

Caldas-Lopes E, Cerchietti L, Ahn J, Clement C, Robles A, Rodina A . Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009; 106(20):8368-73. PMC: 2688867. DOI: 10.1073/pnas.0903392106. View

Baselga J, Gomez P, Greil R, Braga S, Climent M, Wardley A . Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013; 31(20):2586-92. PMC: 5705191. DOI: 10.1200/JCO.2012.46.2408. View

Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M . Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004; 6(6):R605-15. PMC: 1064073. DOI: 10.1186/bcr920. View

Johnson J, Kumar P, Koulnis M, Patel M, Simin K . Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. Cancer Genomics Proteomics. 2014; 11(3):115-26. View

Szyf M . DNA methylation signatures for breast cancer classification and prognosis. Genome Med. 2012; 4(3):26. PMC: 3446276. DOI: 10.1186/gm325. View

Hu X, Zhang J, Xu B, Cai L, Ragaz J, Wang Z . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015; 16(4):436-46. DOI: 10.1016/S1470-2045(15)70064-1. View

Hon J, Singh B, Sahin A, Du G, Wang J, Wang V . Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016; 6(9):1864-1872. PMC: 5043099. View

10.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

11.

Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia J, Hurvitz S . Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013; 19(13):3693-702. DOI: 10.1158/1078-0432.CCR-13-0190. View

12.

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

13.

Gaudet M, Kuchenbaecker K, Vijai J, Klein R, Kirchhoff T, McGuffog L . Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 2013; 9(3):e1003173. PMC: 3609647. DOI: 10.1371/journal.pgen.1003173. View

14.

Douglas J, Iwasawa H, Sun Z, Fedorov A, Ishikado M, Saitoh T . Superconductors: unusual oxygen isotope effects in cuprates?. Nature. 2007; 446(7133):E5. DOI: 10.1038/nature05738. View

15.

Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan Y . FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 30(43):4437-46. DOI: 10.1038/onc.2011.145. View

16.

Lehmann B, Bauer J, Schafer J, Pendleton C, Tang L, Johnson K . PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014; 16(4):406. PMC: 4187324. DOI: 10.1186/s13058-014-0406-x. View

17.

Geyer F, Lacroix-Triki M, Savage K, Arnedos M, Lambros M, Mackay A . β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2010; 24(2):209-31. DOI: 10.1038/modpathol.2010.205. View

18.

Yi Y, Hong W, Kang H, Kim H, Zhao W, Wang A . Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013; 17(5):648-56. PMC: 3822817. DOI: 10.1111/jcmm.12046. View

19.

Liu S, Dontu G, Mantle I, Patel S, Ahn N, Jackson K . Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006; 66(12):6063-71. PMC: 4386278. DOI: 10.1158/0008-5472.CAN-06-0054. View

20.

Takebe N, Harris P, Warren R, Ivy S . Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2010; 8(2):97-106. DOI: 10.1038/nrclinonc.2010.196. View